about
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureusA redesigned vancomycin engineered for dual D-Ala-D-ala And D-Ala-D-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteriaCapturing Biological Activity in Natural Product Fragments by Chemical SynthesisStructure of the complex between teicoplanin and a bacterial cell-wall peptide: use of a carrier-protein approachSynthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: target-accelerated combinatorial synthesis.Enzymatic glycosylation of vancomycin aglycon: completion of a total synthesis of vancomycin and N- and C-terminus substituent effects of the aglycon substrateVancomycin analogs: Seeking improved binding of d-Ala-d-Ala and d-Ala-d-Lac peptides by side-chain and backbone modifications.The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors.Total synthesis of [Ψ[C(═NH)NH]Tpg(4)]vancomycin and its (4-chlorobiphenyl)methyl derivative: impact of peripheral modifications on vancomycin analogues redesigned for dual D-Ala-D-Ala and D-Ala-D-Lac binding.Synthesis and evaluation of selected key methyl ether derivatives of vancomycin aglycon.Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.Vancomycin resistance: small molecule approaches targeting the bacterial cell wall biosynthesis.Vancomycin resistance: occurrence, mechanisms and strategies to combat it.Total syntheses and initial evaluation of [Ψ[C(═S)NH]Tpg⁴]vancomycin, [Ψ[C(═NH)NH]Tpg⁴]vancomycin, [Ψ[CH₂NH]Tpg⁴]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptideTotal synthesis of [Ψ[C(═S)NH]Tpg4]vancomycin aglycon, [Ψ[C(═NH)NH]Tpg4]vancomycin aglycon, and related key compounds: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding.Silver(I)-promoted conversion of thioamides to amidines: divergent synthesis of a key series of vancomycin aglycon residue 4 amidines that clarify binding behavior to model ligandsOritavancin--an investigational glycopeptide antibiotic.Structures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C{19F} and 15N{19F} rotational-echo double resonanceProbing the role of the vancomycin e-ring aryl chloride: selective divergent synthesis and evaluation of alternatively substituted E-ring analogues.Total synthesis and evaluation of [Psi[CH2NH]Tpg4]vancomycin aglycon: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding.Characterization of a regiospecific epivancosaminyl transferase GtfA and enzymatic reconstitution of the antibiotic chloroeremomycin.Synthesis and evaluation of vancomycin aglycon analogues that bear modifications in the N-terminal D-leucyl amino acid.Probing the biology of natural products: molecular editing by diverted total synthesis.Peptidoglycan biosynthesis machinery: a rich source of drug targets.Glycopeptide antibiotics: back to the future.Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.Total Syntheses of Vancomycin-Related Glycopeptide Antibiotics and Key Analogues.Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin.Modification and inhibition of vancomycin group antibiotics by formaldehyde and acetaldehyde.Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria.Developments in Glycopeptide Antibiotics.Lipophilic teicoplanin pseudoaglycon derivatives are active against vancomycin- and teicoplanin-resistant enterococci.New insights into glycopeptide antibiotic binding to cell wall precursors using SPR and NMR spectroscopy.The Carboxyl Terminus of Eremomycin Facilitates Binding to the Non-d-Ala-d-Ala Segment of the Peptidoglycan Pentapeptide Stem.
P2860
Q24556635-76E1677A-9C28-460D-B429-02675D1E6A43Q24607630-2D0277B8-C3EE-4053-94CF-5A087EE2572FQ26772873-CA818546-01B6-439B-B662-96F29B35CF4AQ27676948-2DD0DB48-5850-4D6E-9D0E-809FB91270C1Q30725927-AD14C6FD-83E3-4C61-AD2D-7C5FC395502FQ33855678-F6A58CBA-AB48-408C-BA26-D2C0F610CD98Q33944429-82FA5D04-9D2C-43B8-AE90-B6D6E4740E0FQ33947205-2037D5A0-6BA9-47E5-A5EF-F5907B0D705AQ34282738-7F5DB51B-DA0B-42DA-82FF-1FCA1761E07BQ34308628-23FADF78-215C-4E30-9E28-3023AF0F5435Q34448260-F1AAB83B-E89C-4990-A851-F9AF4C468725Q34587629-B2296495-042C-4744-A3AD-270625AEF149Q35143886-401DF1B7-8807-4039-8893-BAFCAD0B5843Q35224649-2522DDDF-82B6-4279-B9A2-A75C073B2DC5Q35683194-64E477AD-DA4A-4625-BB0D-88774F316737Q36002627-8C193C01-5297-40D3-84F8-6D9B18C4D7A3Q36426011-A2EC7E2F-2394-44C9-A33C-A505639542CAQ36824435-E64BC793-3B0F-4D9B-A42D-084DC46D32B0Q36886883-53CFF98D-F3FE-4B09-9B52-8461913C65FBQ36980378-01BDD36A-779A-4C8D-90C7-64C05C9EB826Q37357546-4BCE4D26-DA41-471C-B2AC-9F08AF2D99C1Q37395641-A14BF5C4-D6BA-422A-BA47-7FE15C026363Q37809500-C3725915-5F13-47A3-B22C-96D082CBC877Q37810971-F5B9B5B9-8CC8-43CA-A1CE-A0B2603A37BDQ38239460-E9C93FC8-C778-4A90-950E-6CF7893B5B02Q38575714-43C94683-EB89-4A81-988E-8982B2891583Q39258608-91D51099-D987-49C1-A29D-326EB605BB49Q41858535-1BCF765C-1D08-4411-B671-04E709AE6AABQ43566025-58698680-E686-40B4-BB28-FB5BE9120CECQ47236751-F9D7B7A1-541B-4BF8-88EB-4CC08B4ECFA4Q47715119-172C4A9D-5564-402A-999B-2B0D1F47CAB1Q51159098-9BFF5F77-83E9-4A99-BE7D-362B62447ABFQ51516313-BC5CFF3D-3CBB-4F43-B911-6F8EFE98F567Q51571264-8E6CAAE4-7363-4B42-AD95-6C215C5EDFF9
P2860
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Structural modifications of glycopeptide antibiotics.
@en
type
label
Structural modifications of glycopeptide antibiotics.
@en
prefLabel
Structural modifications of glycopeptide antibiotics.
@en
P2093
P2860
P1476
Structural modifications of glycopeptide antibiotics.
@en
P2093
A Malabarba
R C Thompson
P2860
P304
P356
10.1002/(SICI)1098-1128(199701)17:1<69::AID-MED3>3.0.CO;2-R
P577
1997-01-01T00:00:00Z